Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

Giulia Martini,Stefania Napolitano,Vincenzo Famiglietti,Filippo de Braud,M. Terminiello,C. Borrelli,Pietro Paolo Vitiello,Antonio Avallone,Nicola Normanno,Evaristo Maiello,Alfredo Falcone,Giuseppe Santabarbara,Carmine Pinto,Daniele Santini,Alessandra Di Liello,Daniela Renato,Lucia Esposito,Francesca Marrone,Teresa Troiani,Davide Ciardiello

Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

2021

3578Background: Promising antitumor activity of so called rechallenge treatment with anti-epidermal growth factor receptor (EGFR) drugs in patients with RAS wild type (RAS WT) metastatic colorectal...

Keywords:

Cancer research
Avelumab
in patient
Growth factor receptor
Medicine
Wild type
antitumor activity
Cetuximab
Skin toxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations